Skip to main content
OpenTrials
Completed

NCT Number: NCT05101590

Hypotension Decision Assist - Use, Safety and Efficacy

This clinical investigation will investigate whether Hypotension Decision Assist (HDA) is a feasible, safe and effective patient clinical decision support system to enhance an anaesthetist's ability to manage a patient's cardiovascular system when undergoing surgery. If successful, this study will provide evidence that the use of HDA facilitates beneficial outcomes for patients who have this device used.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Queen Elizabeth Hospital

Birmingham, B15 2TH, United Kingdom

About this study

In this study participants who are due to undergo elective major surgery and have an arterial line as part of their standard care will be invited to have the additional monitoring device (HDA) included as part of their care. Agreeing participants will have demographic, contact and medical history information necessary to conduct the study recorded, including a record of their intraoperative arterial line measurements.

After completing the consent process participants will receive intraoperative monitoring with Hypotension Decision Assist in addition to their standard care. The HDA monitor will be attached to the patient vital signs monitor, which will in turn be attached to the blood pressure transducer. All sampled arterial line data collected by the patient vital signs monitored will be automatically transmitted in real time to the HDA device via a serial cable attached to a digital export port of the vital signs monitor. HDA will process this input data to display, in graphical and numeric format, vital signs data and physiological parameters derived from the arterial wave form data including: Mean Arterial Pressure (MAP), systolic and diastolic blood pressure, heart rate and changes in heart rate, cardiac output and systemic vascular resistance.

The output from the study will be compared to the primary and secondary outcomes to evaluate the performance and safety of the device and to evaluate whether HDA improves control of the cardiovascular system from the anaesthetists' perspective.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (≥18 years) due to undergo elective surgery who are likely to have an arterial line sited as part of their standard intraoperative care.
  • Recruitment after booking for surgery with sufficient time to read, understand and question study patient information prior to attending for surgery.
  • Ability and willingness to provide informed consent
  • Expected duration of anaesthesia > 60 minutes
  • Intra-arterial monitoring is part of routine clinical care

Exclusion criteria

  • Inability to provide informed consent
  • No arterial line planned as part of their intraoperative care
  • Aged < 18 years of age
  • Patients with aortic regurgitation
  • Patients fitted with an intra-aortic balloon pump (IABP)
  • No other intra-arterial pressure management system in use
  • Concurrent participation in another experimental intervention or drug study

Treatment and study plan

Monitored by HDA

Device

Participants undergoing elective major surgery with an arterial line as part of their standard care and additional monitoring with HDA as part of their care.

Primary outcomes

  1. Display of trends in mean arterial pressure measured in millimetres of mercury (mmHg)

    Time frame: Intraoperative

    Operative time were HDA derives and displays mean arterial pressure (mmHg) data that is relevant to the management of the blood pressure, hemodynamic stability and the cardiovascular system of the patient.

  2. Display of trends in systolic blood pressure measured in millimetres of mercury (mmHg)

    Time frame: Intraoperative

    Operative time were HDA derives and displays systolic blood pressure (mmHg) data that is relevant to the management of the blood pressure, hemodynamic stability and the cardiovascular system of the patient.

  3. Display of trends in diastolic blood pressure measured in millimetres of mercury (mmHg)

    Time frame: Intraoperative

    Operative time were HDA derives and displays diastolic blood pressure (mmHg) data that is relevant to the management of the blood pressure, hemodynamic stability and the cardiovascular system of the patient.

  4. Display of trends in heart rate measured in beats per minute (bpm)

    Time frame: Intraoperative

    Operative time were HDA derives and displays heart rate (bpm) data that is relevant to the management of the blood pressure, hemodynamic stability and the cardiovascular system of the patient.

  5. Display of trends of changes in heart rate (percentage) over the previous five minutes measured as a percentage

    Time frame: Intraoperative

    Operative time were HDA derives and displays changes in heart rate (percentage) data that is relevant to the management of the blood pressure, hemodynamic stability and the cardiovascular system of the patient.

  6. Display of trends of changes in cardiac output (percentage) over the previous five minutes measured as a percentage

    Time frame: Intraoperative

    Operative time were HDA derives and displays changes in cardiac output (percentage) data that is relevant to the management of the blood pressure, hemodynamic stability and the cardiovascular system of the patient.

  7. Display of trends of changes in systemic vascular resistance (percentage) over the previous five minutes measured as a percentage

    Time frame: Intraoperative

    Operative time were HDA derives and displays changes in systemic vascular resistance (percentage) data that is relevant to the management of the blood pressure, hemodynamic stability and the cardiovascular system of the patient.

  8. Adverse events (AEs) related to blood pressure attributable to HDA

    Time frame: Intraoperative

    Incidence, severity and causality of all AEs with delineation of those that are attributable to the use of HDA

Secondary outcomes

  1. Measurement of intraoperative hypotension

    Time frame: Intraoperative

    Measured incidence of Mean Arterial Pressure < 65 for at least 1 minute

  2. Number and type of intervention made by anaesthetists

    Time frame: Intraoperative

    Quantification of interventions related to patient cardiovascular management including fluid administered, cardiovascular active drugs administered and or drug infusion rate changes if applicable

  3. Comparison of HDA projected trend feature

    Time frame: Intraoperative

    Comparison of the estimated MAP at +2mins by projected trend feature versus the observed Mean Arterial Pressure at that time as it arises.

  4. Anaesthetists evaluation of use against a five point Likert-type scale

    Time frame: Intraoperative

    Anaesthetists evaluation of the ease of use and usefulness of HDA ranked in accordance with a five-point Likert-type rating scale where the minimum value is 1 (strongly disagree that HDA is useful or easy to use) and the maximum is 5 (strongly agree that HDA is useful or easy to use) .

Sponsors and collaborators

Lead sponsor

Directed Systems Limited

Industry

Collaborators

  • Innovate UK
  • University Hospital Birmingham NHS Foundation Trust

Registry information

Official study title

A Study of the Use, Safety and Efficacy of the Hypotension Decision Assist Device

Acronym: HDA-USE

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Nov 1, 2021
Registry last updated
Mar 22, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.